Cancer Clinical Trial
Official title:
A Phase I Clinical Study to Determine the Optimal Dose for the Safe Immune Restoration and Immune Response of Allogeneic Cell Immunotherapy (ACIT-1) in Adult Cancer Patients
Verified date | February 2024 |
Source | Cancer Vaccines Limited |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study evaluates four different doses of ACIT-1 for safety and for the ability to raise effective anti-cancer immune responses in patients with pancreatic and other cancers. Approximately half of the patients will have pancreatic cancer and the other half will have other cancers.
Status | Active, not recruiting |
Enrollment | 34 |
Est. completion date | February 2026 |
Est. primary completion date | April 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Histologically confirmed malignancy - Life-expectancy of 3 months or greater - Aged 18 years or above - Willing and able to give written informed consent for participation in the study - Eastern Cooperative Oncology Group performance status of 0,1,2. - Absolute neutrophil count of = 1 x 10e12/m3 - Platelet count of at least 70 x 10e12/m3 - Total bilirubin < 1.5x upper limit of normal; and aspartate transaminase/alanine transaminase (AST/ALT) < 5x upper limit of normal - Creatinine < 1.5x upper limit of normal and/or glomerular filtration rate (GFR) > 40ml/min - Female patients of child bearing potential and male patients whose partner is of child bearing potential must be willing to ensure that they or their partner use effective contraception during the study and for 3 months thereafter - Normal ECG measurements - Able (in the Investigators opinion) and willing to comply with all study requirements - Willing to allow his or her General Practitioner (GP) and consultant, if appropriate, to be notified of participation in the study, and for the GP and/or the National Cancer Registry to be contacted during follow up after the end of treatment. Exclusion Criteria: - Concurrent use of immunosuppressive drugs, in particular systemic steroid therapy, above a threshold of 10mg per day prednisolone equivalent - Evidence of active infection e.g. Hepatitis B, Hepatitis C, HIV or syphilis - Chemotherapy, radiotherapy or biological therapy within 28 days of treatment with the exception of standard of care chemotherapy for pancreatic and haematological cancer patients - Participation in another investigational medicinal product trial within 28 days of treatment - Other vaccination within previous 4 weeks - Antibody treatment within previous 3 months - Major surgery within the 14 days preceding the screening visit - Scheduled elective surgery or other procedures requiring general anaesthesia during the study - Allogeneic graft transplantation recipient - Active systemic autoimmune and allergic disease - Pregnant or lactating females - Significant renal or hepatic impairment as defined by the following: Serum creatinine = 1.5 x upper limit of normal and/or GFR = 40 ml/min. Total bilirubin = 1.5 x upper limit of normal; and AST/ALT = 5 x upper limit of normal - Life threatening illness unrelated to the patient's cancer - Previous history of serious adverse allergic reaction to any medication - Uncontrolled intercurrent illness including, but not limited to, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements - Any other significant disease or disorder which, in the opinion of the Investigator, may either put the participant at risk because of participation in the study, or may influence the result of the study, or the participant's ability to participate in the study. |
Country | Name | City | State |
---|---|---|---|
United Kingdom | The Clatterbridge Cancer Centre NHS Foundation Trust | Bebington | Wirral |
United Kingdom | Royal Liverpool University Hospital | Liverpool | Merseyside |
Lead Sponsor | Collaborator |
---|---|
Cancer Vaccines Limited | Cancer Research UK, Cancer Vaccines Charitable Trust, Liverpool University Hospitals NHS Foundation Trust, National Institute for Health Research, United Kingdom, The Clatterbridge Cancer Centre NHS Foundation Trust, University of Liverpool |
United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Immune responses | Changes in tumour antigen specific immune responses in the blood compared to baseline | Baseline, weeks 4, 8 and 20 | |
Primary | Toxicity | Toxicity based on the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v4.03. | From start of treatment to 20 weeks. | |
Secondary | Clinical benefit | Survival time | From start of treatment up to 14 months. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05346796 -
Survivorship Plan HEalth REcord (SPHERE) Implementation Trial
|
N/A | |
Recruiting |
NCT05094804 -
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
|
Phase 1/Phase 2 | |
Completed |
NCT04867850 -
Effect of Behavioral Nudges on Serious Illness Conversation Documentation
|
N/A | |
Enrolling by invitation |
NCT04086251 -
Remote Electronic Patient Monitoring in Oncology Patients
|
N/A | |
Completed |
NCT01285037 -
A Study of LY2801653 in Advanced Cancer
|
Phase 1 | |
Completed |
NCT00680992 -
Study of Denosumab in Subjects With Giant Cell Tumor of Bone
|
Phase 2 | |
Completed |
NCT00062842 -
Study of Irinotecan on a Weekly Schedule in Children
|
Phase 1 | |
Active, not recruiting |
NCT04548063 -
Consent Forms in Cancer Research: Examining the Effect of Length on Readability
|
N/A | |
Completed |
NCT04337203 -
Shared Healthcare Actions and Reflections Electronic Systems in Survivorship
|
N/A | |
Recruiting |
NCT04349293 -
Ex-vivo Evaluation of the Reactivity of the Immune Infiltrate of Cancers to Treatments With Monoclonal Antibodies Targeting the Immunomodulatory Pathways
|
N/A | |
Terminated |
NCT02866851 -
Feasibility Study of Monitoring by Web-application on Cytopenia Related to Chemotherapy
|
N/A | |
Active, not recruiting |
NCT05304988 -
Development and Validation of the EFT for Adolescents With Cancer
|
||
Completed |
NCT04448041 -
CRANE Feasibility Study: Nutritional Intervention for Patients Undergoing Cancer Surgery in Low- and Middle-Income Countries
|
||
Completed |
NCT00340522 -
Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development
|
||
Recruiting |
NCT04843891 -
Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis.
|
Phase 1 | |
Active, not recruiting |
NCT03844048 -
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
|
Phase 3 | |
Completed |
NCT03109041 -
Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source
|
Phase 1 | |
Completed |
NCT03167372 -
Pilot Comparison of N-of-1 Trials of Light Therapy
|
N/A | |
Terminated |
NCT01441115 -
ECI301 and Radiation for Advanced or Metastatic Cancer
|
Phase 1 | |
Recruiting |
NCT06206785 -
Resting Energy Expenditure in Palliative Cancer Patients
|